subscribeSubscribe
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
FDA
19 Apr 2024
Share Share
Alecensa approved as 1st adjuvant for ALK+ early lung cancer

Alecensa approved as 1st adjuvant for ALK+ early lung cancer
BUSINESSWIRE
18 Apr 2024
Share Share
ESMO: Roche`s Alecensa cuts postsurgery lung cancer recurrence

ESMO: Roche`s Alecensa cuts postsurgery lung cancer recurrence
Angus Liu FIERCE PHARMA
21 Oct 2023
Share Share
Genentech’s Alecensa Reduces the Risk of Death by an Unprecedented 76%

Genentech’s Alecensa Reduces the Risk of Death by an Unprecedented 76%
BUSINESSWIRE
18 Oct 2023
Share Share
Roche claims study success for targeted drug in early lung cancer

Roche claims study success for targeted drug in early lung cancer
Ben Fidler BIOPHARMADIVE
02 Sep 2023
Share Share
Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC

Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC
ONCLIVE
01 Sep 2023
Share Share
Roche`s Alecensa stays on top of Xalkori at 5-year mark

Roche`s Alecensa stays on top of Xalkori at 5-year mark
Carly Helfand FIERCE PHARMA
13 May 2020
Share Share
NICE final guidance backs Pfizer`s Lorviqua

NICE final guidance backs Pfizer`s Lorviqua
Selina McKee PHARMA TIMES
13 May 2020
Share Share
New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment

New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment
GLOBENEWSWIRE
07 May 2020
Share Share
FDA Confirms Paragraph IV Patent Challenge of Alecensa 208434 (Alectinib 150 mg)Capsules

FDA Confirms Paragraph IV Patent Challenge of Alecensa 208434 (Alectinib 150 mg)Capsules
FDA
15 Feb 2020
Share Share